Image
What’s Next Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis

Anne Maitland, MD, PhD

This activity is jointly provided by Global Education Group and Integritas Communications. This activity is endorsed by The Mast Cell Disease Society, Inc.

 

This educational activity is supported by an educational grant from Blueprint Medicines Corporation.

Faculty

Anne Maitland, MD, PhD
Assistant Clinical Professor, Icahn School of Medicine
Department of Medicine Allergy & Clinical Immunology
Consulting Physician, Clinical Paradigms, LLC
New York, New York

Program Description

Systemic mastocytosis (SM) is a group of rare disorders characterized by accumulation of mast cells in internal tissues and organs, such as the liver, spleen, bone marrow, and small intestines. Patients with SM experience symptoms that include anaphylaxis, flushing, gastrointestinal issues, fatigue, and skin lesions; the lack of specific symptoms often makes diagnosis challenging. Clinicians need to be aware of the array of symptoms and signs that could indicate SM and necessitate further patient evaluation. More than 90% of patients with SM have a KIT D816V mutation, which, along with results of serum tryptase levels and bone marrow biopsy, is key to diagnosing SM. Management strategies for nonadvanced SM are largely symptomatic treatment, though there are targeted therapies in clinical trials. During this Point-of-Care 201TM educational activity, learners will review the evidence and best-practice recommendations for early diagnosis and treatment of nonadvanced SM, including keys to differential diagnosis, recommendations for management, and results and progress from new clinical trials. Brief videos of expert faculty reinforcing key practices in SM management are interpolated throughout this educational activity.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians involved in the care of patients with nonadvanced systemic mastocytosis.

Learning Objectives

After completing this activity, participants will be better prepared to:

  • Evaluate patients to accelerate the differential diagnosis of nonadvanced systemic mastocytosis and longitudinally assess treatment responses

  • Describe the clinical profiles and trial results for current and emerging targeted treatment options in nonadvanced systemic mastocytosis

  • Construct treatment regimens for patients with nonadvanced systemic mastocytosis to reflect symptomatology, disease burdens, evidence for efficacy and safety, and shared clinical decision-making

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Anne Maitland, MD, PhD  - Nothing to disclose.

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to received credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Education Group Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.50

credit type CME/CE

release 11/30/2022

expiration 11/30/2023